Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Commodities

Almonty Shares Slide Despite Strategic Expansion Moves

Robert Sasse by Robert Sasse
November 5, 2025
in Commodities, Earnings, Value & Growth
0
Almonty Stock
0
SHARES
36
VIEWS
Share on FacebookShare on Twitter

Almonty Industries witnessed a significant 9.4% decline in its share price, closing at CAD $9.03, as disappointing quarterly operational results overshadowed positive corporate developments. The Canadian tungsten producer reported a 28% revenue increase to CAD $8.7 million but failed to meet market expectations.

The company posted an operating loss of CAD $2.2 million, substantially below analyst projections. In a surprising twist, Almonty recorded a net profit of CAD $33.2 million, primarily driven by financial instrument revaluations that offset operational challenges.

Strategic Acquisition Positions Company for US Defense Contracts

Beyond the quarterly figures, Almonty executed a strategic masterstroke with its recent acquisition of the Gentung-Browns Lake tungsten project in Montana for $10 million. This purchase could establish the company as a primary tungsten supplier to the United States defense sector.

CEO Lewis Black confirmed that production at the Montana site could commence as early as the second half of 2026. This timeline aligns perfectly with the US Department of Defense’s planned 2027 prohibition on tungsten sourcing from China, Russia, and North Korea.

Key advantages of the Montana project include:
* An existing 15-year offtake agreement with a US defense contractor
* Contractual coverage for over 90% of initial production capacity
* Utilization of processed equipment from Spanish operations
* Established water rights and infrastructure accelerating development

Should investors sell immediately? Or is it worth buying Almonty?

Global Expansion Strategy Advances Simultaneously

While pursuing its US offensive, Almonty continues to advance projects across Europe and Asia. At its flagship Panasqueira operation in Portugal, the company launched an extensive drilling program targeting Level 4 – a new production tier expected to extend mine life and boost annual output.

In South Korea, drilling activities at the Sangdong project – one of the largest tungsten deposits outside China – are focusing on the molybdenum component. This strategic move addresses global shortages of this critical metal directly.

Market analysts remain cautiously optimistic about Almonty’s prospects. DA Davidson maintains its “Buy” recommendation with a US $11.00 price target, indicating confidence in the company’s long-term strategy despite current operational headwinds.

Critical Months Ahead for Execution

The coming months will prove decisive for Almonty’s trajectory. Regulatory approvals in Montana and drilling results from Portugal will demonstrate whether the company can translate strategic positioning into operational success. If successfully executed, Almonty stands to benefit disproportionately from ongoing trade conflicts and supply chain restructuring.

Nevertheless, significant challenges persist. Concurrent development of multiple projects, substantial capital requirements, and operational inefficiencies continue to pressure the company’s financial performance. Investors now face the crucial decision of whether the recent price decline represents a buying opportunity or signals further downward momentum.

Ad

Almonty Stock: Buy or Sell?! New Almonty Analysis from February 7 delivers the answer:

The latest Almonty figures speak for themselves: Urgent action needed for Almonty investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Almonty: Buy or sell? Read more here...

Tags: Almonty
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Embecta Stock
Earnings

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock
Consumer & Luxury

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Next Post
La-Z-Boy Stock

La-Z-Boy Shares Plummet to New Low Ahead of Critical Earnings Report

Nel ASA Stock

Norwegian Hydrogen Leader Faces Mounting Challenges

Compass Therapeutics Stock

Compass Therapeutics Shares Surge on Promising Cancer Drug Data

Recommended

Fiserv Stock

Fiserv Shares Struggle to Gain Traction Amid Investor Doubts

3 weeks ago
Cooper-Standard Stock

Cooper-Standard Shares Plunge on Disappointing Earnings Report

3 months ago
Volatus Aerospace Stock

Volatus Aerospace Expands Defense and Environmental Technology Operations

5 months ago
FCBC stock news

Symmetry Partners LLC Acquires Significant Position in Carnival Co. & plc, Expresses Optimism for Future Growth

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Trending

Embecta Stock
Earnings

Embecta’s Q1 Performance Outpaces Analyst Forecasts

by Rodolfo Hanigan
February 7, 2026
0

Medical device company Embecta reported financial results for the first quarter of fiscal year 2026 on Thursday,...

Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Embecta’s Q1 Performance Outpaces Analyst Forecasts
  • Camping World’s New Leadership Faces First Major Test
  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com